Price$0.62-0.02 (-2.89%)
01:30 PM07:45 PM
News · 26 weeks62-44%
2025-12-142026-06-07
Mix2790d
- SEC Filings12(44%)
- Other8(30%)
- Insider3(11%)
- Offering2(7%)
- Analyst1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERChief Executive Officer Lucas Brent T. was granted 32,856 shares, increasing direct ownership by 11% to 329,946 units (SEC Form 4)4 - Envoy Medical, Inc. (0001840877) (Issuer)
- PREnvoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18thWhite Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ:COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026Location: Bellagio Hotel & Casino, Las Vegas, NVBooth: #410Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M. PTPresentation Location: Track 7 - Donatello 3Webcast: Viewable hereThe Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedul
- SECEnvoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Envoy Medical, Inc. (0001840877) (Filer)
- PREnvoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing TechnologyAustralian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge SafetyWhite Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ:COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry. "As we continue advancing fully implanted hearing technology, protecting the innovation beh
- SECEnvoy Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Envoy Medical, Inc. (0001840877) (Filer)
- SECSEC Form SCHEDULE 13G filed by Envoy Medical Inc.SCHEDULE 13G - Envoy Medical, Inc. (0001840877) (Subject)
- SECSEC Form SCHEDULE 13G filed by Envoy Medical Inc.SCHEDULE 13G - Envoy Medical, Inc. (0001840877) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Envoy Medical Inc.SCHEDULE 13G/A - Envoy Medical, Inc. (0001840877) (Subject)
- SECSEC Form 10-Q filed by Envoy Medical Inc.10-Q - Envoy Medical, Inc. (0001840877) (Filer)
- SECEnvoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Envoy Medical, Inc. (0001840877) (Filer)
- PREnvoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear ImplantCompany Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry ConferencesWhite Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant."The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and th
- PREnvoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear ImplantPositive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early MayDetails to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ETWhite Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the first podium presentations of clinical data from the first stage of its pivotal clinical study of the investigational Acclaim® cochlear implant, a first-of-its-kind, fully implanted cochlear implant system. The Company w
- PREnvoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear ImplantAll 56 Enrolled Subjects Have Been Through Their Activation Visit Firming Up Study TimelineWhite Bear Lake, Minnesota--(Newsfile Corp. - April 22, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully implanted Acclaim® cochlear implant have been through their "Activation Visits," when a patient's device is initially turned on for the first time. "The conclusion of our trial studying the first-of-its-kind fully implanted Acclaim® cochlear implant is now within sight," said Brent Lucas, Ch
- SECEnvoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Envoy Medical, Inc. (0001840877) (Filer)
- INSIDERSEC Form 4 filed by Mckhann Chas4 - Envoy Medical, Inc. (0001840877) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mckhann Chas3 - Envoy Medical, Inc. (0001840877) (Issuer)
- PREnvoy Medical Appoints Chas McKhann to Board of DirectorsProven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder valu
- SECAmendment: SEC Form 10-K/A filed by Envoy Medical Inc.10-K/A - Envoy Medical, Inc. (0001840877) (Filer)
- SECSEC Form DEFA14A filed by Envoy Medical Inc.DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)
- SECSEC Form DEF 14A filed by Envoy Medical Inc.DEF 14A - Envoy Medical, Inc. (0001840877) (Filer)
- PREnvoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear ImplantCompany Remains on Schedule for PMA Submission to FDAWhite Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's progress.The first three pivotal trial patients implanted at the start of 2025 are now the first to reach the 12-month follow-up evaluation point. The primary endpoints for the trial are tied to 12-month data. Achieving this critic
- SECEnvoy Medical Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant8-K - Envoy Medical, Inc. (0001840877) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on Envoy Medical with a new price targetH.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50
- SECEnvoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Envoy Medical, Inc. (0001840877) (Filer)
- SECSEC Form PRE 14A filed by Envoy Medical Inc.PRE 14A - Envoy Medical, Inc. (0001840877) (Filer)
COCH FAQ
6 questionsWhere does COCH stock trade?
Envoy Medical Inc. (COCH) is listed on NASDAQ.What sector and industry is COCH in?
Envoy Medical Inc. operates in the Health Care sector, Industrial Specialties industry.When did Envoy Medical Inc. go public?
Envoy Medical Inc. (COCH) completed its IPO in 2021.What are analysts saying about COCH?
Envoy Medical Inc. has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $250.00 price target on 2026-03-31. Recent price targets range from $250.00 to $850.00.What companies are similar to COCH?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare COCH side-by-side with any of them on Quantisnow.How can I track COCH on Quantisnow?
Quantisnow aggregates Envoy Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow COCH to receive live email and push alerts on every new disclosure.